V. Hoang

发表

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer

E. Martin, L. Rhodes, S. Elliott, 2018, Breast Cancer Research and Treatment.

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model

E. Martin, S. Elliott, B. Collins-Burow, 2018, Oncoscience.

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation

K. Nephew, B. Rowan, E. Martin, 2016, Non-coding RNA.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators

D. Chrisey, B. Rowan, L. Rhodes, 2014, Breast Cancer Research and Treatment.

A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways

K. Nephew, D. Rusch, D. Drewry, 2020, Anti-cancer drugs.

The role of MEK1/2 and MEK5 in melatonin‐mediated actions on osteoblastogenesis, osteoclastogenesis, bone microarchitecture, biomechanics, and bone formation

P. Witt-Enderby, M. Burow, O. Mohiuddin, 2022, Journal of pineal research.

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells

D. Drewry, W. Zuercher, E. Martin, 2021, Oncology letters.

MEK 5-ERK 5 Signaling in Cancer : Implications for Targeted Therapy

Jane E. Cavanaugh, M. Burow, V. Hoang, 2018 .

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer

Jane E. Cavanaugh, M. Burow, Mohit Gupta, 2019, Front. Oncol..

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes

D. Drewry, W. Zuercher, C. Wells, 2017, PloS one.

Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression

B. Rowan, B. Collins-Burow, M. Burow, 2017, Molecular Cancer Research.

Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.

J. Madura, Jane E. Cavanaugh, M. Burow, 2018, Bioorganic & medicinal chemistry letters.

Oncogenic signaling of MEK5-ERK5.

Jane E. Cavanaugh, M. Burow, B. Beckman, 2017, Cancer letters.

ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer

K. Nephew, L. Del Valle, Jane E. Cavanaugh, 2020, Frontiers in Oncology.

MicroRNA‐335‐5p and ‐3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance

K. Nephew, D. Rusch, E. Martin, 2017, FEBS letters.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1

K. Nephew, D. Rusch, E. Martin, 2015, Oncogenesis.

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer

K. Nephew, D. Rusch, Jane E. Cavanaugh, 2021, Oncoscience.

Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple‐negative breast cancer through FRA‐1 regulation

K. Nephew, D. Rusch, D. Chrisey, 2021, Journal of cellular biochemistry.

Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.

J. Madura, Jane E. Cavanaugh, M. Burow, 2018, Bioorganic & medicinal chemistry letters.

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model

B. Rowan, E. Martin, L. Rhodes, 2019, BMC Cancer.

NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells

K. Nephew, D. Drewry, W. Zuercher, 2021, Breast Cancer Research and Treatment.